Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind trial of PROSTVAC-V/F ± GM-CSF in metastatic castrate-resistant prostate cancer
2010-021196-85Phase 3Terminated
- Sponsor
- Bavarian Nordic
- Start
- Nov 2011
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing PROSTVAC-V/F + GM-CSF, PROSTVAC-V/F alone and Placebo (3 arms). Primary endpoint: Overall survival. Started Nov 2011; status: terminated.
02
Drugs
rilimogene galvacirepvecsargramostim
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2010-021196-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021196-85.